Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection

Phase 4

Withdrawn

• Conditions: Urinary Tract Infection
• Interventions: Drug: Hyaluronic Acid

• Registration Number: NCT02034890
• Lead Sponsor: Rabin Medical Center

Brief Summary

Prospective trial which includes instillation of intravesical hyaluronic acid in an attempt to reduce the incidence of urinary tract infections in patients after orthotopic neobladder reconstruction.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-01-10
• Study First Submitted QC: 2014-01-10
• Study First Posted: 2014-01-14
• Study Start: 2015-07
• Status Verified: 2016-04
• Primary Completion: 2017-03
• Last Update Submitted: 2019-04-22
• Last Update Posted: 2019-04-24

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• patients undergoing radical cystectomy and orthotopic neobladder reconstruction

Exclusion Criteria

• patients <18 years and unwilling to participate in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
hyaluronic acid	Hyaluronic Acid	intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively

Primary Outcome Measures

Name	Time	Method
positive urinary culture	6 months

Secondary Outcome Measures

Name	Time	Method
urinary tract infection	6 months

Trial Locations

Locations (1)

Urology department, Rabin Medical Center; 🇮🇱 Petach Tiqva, Israel